Arginine counteracts the inhibitory effect of recombinant human insulin-like growth factor I on the somatotroph responsiveness to growth hormone-releasing hormone in humans

Journal of Clinical Endocrinology and Metabolism

Volumn 85, Issue 10, 2000, Pages 3604-3608

  Gianotti, Laura ^a   Maccario, Mauro ^a   Lanfranco, Fabio ^a   Ramunni, Josefina ^a   Di Vito, Lidia ^a   Grottoli, Silvia ^a   Muller, Eugenio Edoardo ^b   Ghigo, Ezio ^a,c   Arvat, Emanuela ^a  

^a UNIVERSITY OF TURIN   (Italy)

^b UNIVERSITY OF MILAN   (Italy)

^c MOLINETTE HOSPITAL   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ARGININE; GLUCOSE; GROWTH HORMONE; GROWTH HORMONE RELEASING FACTOR; INSULIN; PLACEBO; RECOMBINANT SOMATOMEDIN C;

ADULT; ARTICLE; CONTROLLED STUDY; FEMALE; GLUCOSE BLOOD LEVEL; GROWTH HORMONE RELEASE; HORMONE DETERMINATION; HUMAN; HUMAN EXPERIMENT; HYPOTHALAMUS; INSULIN BLOOD LEVEL; NEGATIVE FEEDBACK; PRIORITY JOURNAL;

EID: 0033762856     PISSN: 0021972X     EISSN: None     Source Type: Journal    
DOI: 10.1210/jc.85.10.3604     Document Type: Article

References (47)

1. Somatomedin-C mediates growth hormone negative feedback by effects on both the hypothalamus and the pituitary
2. Human growth hormone and somatomedin C suppress the spontaneous release of growth hormone in unanesthetized rats
3. Insulin-like growth factors: A role in growth hormone negative feedback and body weight regulation via brain
4. The growth hormone (GH)-releasing hormone (GHRH)-GH-somatomedin axis: Evidence for rapid inhibition of GHRH-elicited GH release by insulin-like growth factors I and II
5. Short-term metabolic effects of recombinant human insulin-like growth factor I in healthy adults
6. Effect of recombinant insulin-like growth factor I on insulin secretion and renal function in normal human subjects
7. Biochemical and hormonal changes induced by one week of administration of rhIGF-I to patients with Laron type dwarfism
8. A low dose euglycemic infusion of recombinant human insulin-like growth factor I rapidly suppresses fasting-enhanced pulsatile growth hormone secretion in humans
9. Negative feedback regulation of pulsatile growth hormone secretion by insulin-like growth factor I
10. The effect of recombinant IGF-I on anterior pituitary function in healthy volunteers
11. IGF feedback effects on growth hormone secretion in ewes: Evidence for action at the pituitary but not the hypothalamic level
12. Recovery of growth hormone release from suppression by exogenous insulin-like growth factor I (IGF-I): Evidence for a suppressive action of free rather than bound IGF-I
13. Regulatory mechanisms of growth hormone secretion are sexually dimorphic
14. Effects of recombinant human insulin-like growth factor I administration on growth hormone (GH) secretion, both spontaneous and stimulated by GH-releasing hormone or hexarelin, a peptidyl GH secretagogue, in humans
15. Identification of binding sites for an insulin-like growth factor (IGF-I) in the median eminence of the rat brain by quantitative autoradiography
16. Insulin-like growth factor I action on rat anterior pituitary cells: Suppression of growth hormone secretion and messenger ribonucleic acid levels
17. Differential effects of central and peripheral administration of GH and insulin-like growth factor on hypothalamic GH-releasing hormone and somatostatin gene expression in GH-deficient dwarf rats
18. In vitro release of growth hormone-releasing factor from rat hypothalamus: Effect of insulin-like growth factor-I
19. Reduction of plasma immunoreactive somatomedin C during fasting in humans
20. Growth regulation and its alteration in disease states
21. Acquired growth hormone resistance
22. Multiple endocrine abnormalities of the growth hormone and insulin-like growth factor axis in patients with anorexia nervosa: Effect of short- and long-term weight recuperation
23. Hormonal and metabolic effects and pharmacokinetics of recombinant insulin-like growth factor-I in growth hormone receptor deficiency/Laron syndrome
24. The relationship between overnight GH levels and insulin concentrations in adolescents with insulin-dependent diabetes mellitus (IDDM) and the impact of recombinant human insulin-like growth factor-I (rhIGF-I)
25. Administration of human recombinant insulin-like growth factor-I in critically ill patients
26. Atypical growth hormone releasing peptides
27. Growth hormone-releasing peptides
28. Peptidomimetic regulation of growth hormone secretion
29. Effect of acute administration of insulin-like growth factor I in patients with Laron-type dwarfism
30. Intravenous administration of recombinant IGF-I lowers serum GHRH and TSH
31. Regulation of GH secretion
32. Pathophysiology of the neuroregulation of growth hormone secretion in experimental animals and the human
33. Neuroendocrine control of growth hormone secretion
34. Effects of repeated subcutaneous administration of recombinant human insulin-like growth factor I in adults with growth hormone deficiency
35. IGF-1 attenuates the GH response to arginine
36. New modalities for understanding dynamic regulation of the somatotropic (GH) axis: Explication of gender differences in GH neuroregulation in the human
37. Growth hormone (GH) responsiveness to combined administration of arginine and GH-releasing hormone does not vary with age in man
38. Arginine stimulates GH secretion by suppressing endogenous somatostatin secretion
39. Repetitive GHRH and arginine administration to explore the maximal secretory capacity of somatotroph cells during lifespan
40. Arginine abolishes the inhibitory effect of glucose on the GH response to GHRH in man
41. The somatopause
42. Human growth hormone and human aging
43. Human aging and the GH/IGF-I axis
44. Pyridostigmine partially restores the GH responsiveness to GHRH in normal aging
45. Endogenous growth hormone (GH)-releasing hormone is required for GH responses to pharmacological stimuli
46. Effects of GH and IGF-I administration on GHRH and somatostatin mRNA levels. I. A study on ad libitum fed and starved adult male rats
47. Genesis of episodic growth hormone secretion